After cardiac arrest, your patient achieves return of spontaneous circulation but remains unconscious. You know the next 72 hours are critical. Brain injury from the initial arrest and subsequent reperfusion can worsen without proper intervention. Temperature control becomes one of your most powerful tools, yet many clinicians remain uncertain about the practical steps involved.
Targeted temperature management prevents fever and maintains controlled body temperature to reduce secondary brain injury and improve neurological outcomes. Current evidence supports actively preventing temperature above 37.5°C in all comatose post-arrest patients. The technique requires careful patient selection, appropriate cooling methods, vigilant monitoring, and controlled rewarming.
This guide walks you through each step of targeted temperature management for cardiac arrest patients. You will learn how to confirm indications, stabilise your patient, select appropriate target temperatures, initiate cooling while managing shivering, monitor for complications, and execute controlled rewarming. We have included practical considerations for Australian healthcare settings, aligned with ANZCOR guidelines and current evidence. By the end, you will have a clear framework for implementing this evidence-based intervention in your practice.
What targeted temperature management is
Targeted temperature management refers to the deliberate control of body temperature in comatose patients after cardiac arrest. You actively prevent fever and maintain a specific temperature range to protect the brain from secondary injury. The approach has evolved from deep hypothermia protocols of the past to current strategies that focus primarily on preventing hyperthermia while maintaining normothermia or mild hypothermia.
The core principle
Your goal centres on preventing temperatures above 37.5°C for at least 72 hours after return of spontaneous circulation. Current evidence emphasises fever prevention as the minimum standard of care for all comatose post-arrest patients. Whether you target hypothermia (32-34°C), normothermia (36-37.5°C), or simply prevent fever depends on your institutional protocols and patient characteristics. The critical element remains active temperature control rather than passive observation.
ANZCOR guidelines recommend against routine pre-hospital cooling with large volumes of cold intravenous fluid. Instead, you begin structured temperature management once your patient arrives and stabilisation is complete. The approach requires continuous core temperature monitoring, appropriate cooling devices, and careful attention to prevent both overshooting your target and rebound hyperthermia.
Why temperature control matters
Brain injury after cardiac arrest develops in two phases. The initial ischaemic insult occurs during the arrest itself, when cerebral blood flow stops. Reperfusion injury follows after you restore circulation, triggering inflammatory cascades, free radical production, and cellular death that can continue for days. Elevated temperature accelerates these destructive processes.
Every degree of fever increases cerebral metabolic rate by 5-7%, worsening the supply-demand mismatch in already vulnerable brain tissue. Controlled temperature slows harmful enzymatic reactions, reduces excitatory neurotransmitter release, suppresses inflammation, and decreases free radical formation. These mechanisms combine to limit secondary brain injury and improve your patient’s chances of meaningful neurological recovery.
Temperature control represents one of the few evidence-based interventions available to reduce brain injury after successful resuscitation from cardiac arrest.
Understanding how to do targeted temperature management effectively requires recognising that even small temperature elevations can worsen outcomes, making vigilant monitoring and prompt intervention essential components of post-arrest care.
Step 1. Confirm indications and exclusions
Before you initiate any cooling protocol, you must systematically verify that your patient meets the criteria for targeted temperature management. This decision point determines whether you proceed with active temperature control or pursue alternative post-arrest care strategies. The assessment takes only minutes but prevents inappropriate application of a resource-intensive intervention that carries potential risks when used incorrectly.
Who qualifies for temperature management
You should apply targeted temperature management to any adult patient who remains comatose after achieving return of spontaneous circulation from cardiac arrest. Comatose means your patient does not follow commands and has a Glasgow Coma Scale score of 8 or less. The initial cardiac rhythm does not change this indication; both shockable rhythms (ventricular fibrillation, pulseless ventricular tachycardia) and non-shockable rhythms (asystole, pulseless electrical activity) qualify equally.
Out-of-hospital cardiac arrest represents the most common scenario, accounting for roughly 80% of cases where you will implement temperature management. In-hospital cardiac arrest patients also qualify when they remain unconscious after resuscitation. The location of arrest matters less than the neurological status after return of spontaneous circulation. Your assessment begins once you confirm stable circulation and adequate oxygenation.
Consider these qualifying criteria:
- Patient achieved return of spontaneous circulation after cardiac arrest
- Patient remains unresponsive and unable to follow commands
- Glasgow Coma Scale score ≤ 8
- Cardiac arrest presumed to be of cardiac origin
- Haemodynamic stability achieved or achievable with vasopressor support
Absolute contraindications
Certain conditions exclude your patient completely from targeted temperature management due to unacceptable risk of harm. You must identify these before beginning any cooling protocol because proceeding could worsen outcomes or precipitate catastrophic complications.
Active uncontrolled bleeding represents the most important absolute contraindication. Hypothermia impairs coagulation cascade function and platelet aggregation, making any existing haemorrhage worse. Cardiac arrest caused by trauma also excludes your patient, as these cases involve different pathophysiology and management priorities that take precedence over temperature control.
Intracranial haemorrhage or haemorrhagic stroke discovered on initial imaging absolutely contraindicates cooling. Patients with severe pre-existing coagulopathy (INR >3.0, platelets <50 × 10⁹/L) face unacceptable bleeding risk. If your patient has refractory haemodynamic instability despite maximal vasopressor support, you cannot safely implement temperature management.
Identifying absolute contraindications protects your patient from interventions that could cause more harm than benefit in specific clinical scenarios.
Relative contraindications to consider
Several conditions require careful consideration but do not automatically exclude your patient from temperature management. You weigh the potential benefits against individual risks based on your patient’s complete clinical picture and available resources.
Pre-existing severe infection or sepsis increases complication risk because hypothermia suppresses immune function. Prolonged arrest time (downtime >60 minutes) suggests severe initial injury that may limit benefit. Patients with known terminal illness or advanced directives limiting aggressive care warrant discussion with families before proceeding. Pregnancy requires specialised consideration, though it does not represent an absolute contraindication. Your clinical judgement determines whether these relative factors outweigh potential neurological benefits in each specific case.
Step 2. Stabilise and prepare the patient
You cannot safely implement temperature management until your patient achieves baseline physiological stability. This preparation phase prevents complications and ensures you can maintain controlled conditions throughout the cooling, maintenance, and rewarming periods. Rushing into cooling before proper stabilisation increases the risk of cardiac arrhythmias, haemodynamic collapse, and equipment failures that compromise your temperature control protocol.
Secure airway and optimise ventilation
Your patient requires definitive airway control before you begin targeted temperature management. Endotracheal intubation with mechanical ventilation remains the standard approach for all comatose post-arrest patients. The tube provides airway protection during prolonged unconsciousness, prevents aspiration, allows precise control of oxygenation and ventilation, and facilitates the sedation needed to manage shivering.
Set your ventilator to achieve specific physiological targets that protect the brain and support optimal conditions for temperature control. Maintain oxygen saturation between 94-98% using the minimum FiO2 necessary, as hyperoxia correlates with worse neurological outcomes. Target PaCO2 between 35-45 mmHg because hypocapnia causes cerebral vasoconstriction that reduces blood flow to already vulnerable brain tissue, whilst hypercapnia increases intracranial pressure.
Document baseline arterial blood gas values immediately after stabilisation. These results guide your ongoing ventilator adjustments and provide comparison points as temperature changes affect acid-base balance. Hypothermia shifts the oxygen-haemoglobin dissociation curve left, reducing oxygen release to tissues, which makes maintaining appropriate saturation ranges even more critical during cooling phases.
Establish haemodynamic stability
Adequate blood pressure ensures cerebral perfusion throughout your temperature management protocol. Target mean arterial pressure above 65 mmHg as the minimum acceptable threshold, though higher targets (80 mmHg systolic) may benefit patients with chronic hypertension. Insert an arterial line for continuous monitoring because non-invasive measurements become less reliable during vasoconstriction induced by cooling.
Central venous access provides the route for vasopressor infusions and fluid administration you will need. Place a central line before initiating cooling to avoid catheter insertion during hypothermia when coagulopathy and vasoconstriction complicate the procedure. Noradrenaline remains the first-line vasopressor when you require pharmacological support, titrated to maintain your target blood pressure.
Haemodynamic stability must precede cooling because hypothermia-induced peripheral vasoconstriction and decreased cardiac output can precipitate cardiovascular collapse in unstable patients.
Volume status requires optimisation before cooling begins. Cold diuresis occurs during hypothermia as peripheral vasoconstriction shifts blood centrally, increasing atrial natriuretic peptide release whilst suppressing antidiuretic hormone. Adequate preload prevents hypovolaemia during the maintenance phase. Consider a 500ml crystalloid bolus if your patient shows signs of volume depletion, but avoid excessive fluid that could worsen pulmonary oedema in patients with post-arrest myocardial dysfunction.
Set up core temperature monitoring
Accurate continuous temperature measurement determines how to do targeted temperature management effectively. Core temperature monitoring must begin before you start any cooling intervention to establish baseline values and guide your cooling rate. Peripheral temperature sites produce unreliable readings during vasoconstriction and fail to reflect true core values.
Oesophageal temperature probes provide the most accurate core measurements with minimal lag time. Insert the probe 32-38 cm from the teeth into the distal oesophagus where readings closely approximate blood temperature. Bladder temperature represents an acceptable alternative using a specialised urinary catheter with integrated thermistor. Avoid relying solely on bladder temperature if urine output drops below 50 ml/hour because stagnant urine fails to reflect changing core values. Rectal probes work but demonstrate longer lag times that can lead to overshooting your target during rapid cooling.
Prepare cooling equipment and medications
Your cooling system must be operational before you begin. Select either surface cooling devices or endovascular catheters based on institutional availability and patient factors. Surface systems using water-circulating pads offer non-invasive application suitable for most patients. Endovascular systems provide faster cooling rates and tighter temperature control but require central venous catheterisation and carry infection risk.
Prepare medications you will need to manage shivering, the primary obstacle to effective cooling:
- Sedation: Propofol infusion or midazolam
- Analgesia: Fentanyl or morphine infusion
- Shivering suppression: Buspirone, dexmedetomidine, or pethidine
- Neuromuscular blockade: Rocuronium or vecuronium (if other measures fail)
Stock your patient’s bedside with equipment for physical cooling methods. Gather ice packs for neck, axillae, and groins as adjuncts to accelerate initial cooling. Prepare cold intravenous fluids (4°C normal saline) for rapid infusion if you need to lower temperature quickly, though limit total volume to 30 ml/kg to avoid fluid overload complications.
Step 3. Choose target temperature and duration
Your temperature target must balance the available evidence with your institutional protocols and patient characteristics. The decision determines your cooling intensity, monitoring requirements, and medication needs throughout the treatment period. Current evidence supports fever prevention as the minimum standard for all comatose post-arrest patients, whilst deeper hypothermia remains controversial following recent trial results.
Current temperature targets
ANZCOR guidelines recommend preventing fever by maintaining temperature at or below 37.5°C as the primary goal for all comatose patients after cardiac arrest. This approach requires active intervention rather than passive observation because many post-arrest patients develop hyperthermia without temperature control measures. You actively prevent temperature elevation through cooling devices, medication, and environmental adjustments.
Whether you target hypothermia (32-34°C) or normothermia (36-37.5°C) depends on your institution’s protocol and emerging evidence. The TTM2 trial found no significant difference in outcomes between 33°C and controlled normothermia, shifting practice towards less aggressive cooling. Most Australian centres now target normothermia (36-37°C) whilst remaining vigilant about fever prevention. Some institutions continue hypothermia protocols for specific patient subgroups, though evidence supporting this approach remains limited.
The critical element of how to do targeted temperature management effectively lies in preventing fever rather than achieving a specific hypothermic temperature.
You may encounter patients arriving with spontaneous mild hypothermia (34-36°C) after prolonged resuscitation. ANZCOR recommends against actively warming these patients to normothermia. Instead, allow passive rewarming or maintain the lower temperature if your protocol supports it, as the mild hypothermia may provide neuroprotection without additional intervention.
Duration of control phases
Your temperature management protocol extends through three distinct time periods requiring different approaches. The maintenance phase lasts 24 hours minimum if you target hypothermia, during which you hold temperature at your chosen target through continuous device adjustment and shivering management. Fever prevention continues for at least 72 hours regardless of your initial temperature target, representing the period of highest risk for secondary brain injury.
Plan your timeline from the moment you achieve target temperature, not from arrest or hospital arrival. If cooling takes 4 hours, your 24-hour maintenance period begins at that point. Document specific times for each phase transition in your medical record to coordinate nursing handovers and medication adjustments. After completing maintenance, you initiate controlled rewarming at 0.2-0.5°C per hour until reaching 36-37°C, a process requiring 6-10 hours depending on your starting temperature.
Beyond 72 hours, continue monitoring for fever and treat any elevation above 37.5°C promptly. Rebound hyperthermia commonly occurs when you discontinue active cooling, requiring ongoing vigilance even after your formal protocol ends.
Step 4. Start cooling and control shivering
You begin cooling once your patient achieves physiological stability and core temperature monitoring is operational. The cooling phase demands constant attention because rapid temperature drops can trigger dangerous arrhythmias whilst inadequate cooling fails to reach your target within the optimal timeframe. Your primary challenge becomes shivering, the body’s natural thermogenic response that fights your cooling efforts and increases metabolic demand in already stressed tissues.
Initiating the cooling process
Start your cooling device according to the manufacturer’s instructions and set the target temperature based on your institutional protocol. Surface cooling systems typically require 2-4 hours to reach a target of 33-36°C from normal body temperature, whilst endovascular systems cool faster at approximately 1.5°C per hour. Document your start time and initial core temperature to track your cooling rate and identify any problems with device function or patient response.
Apply ice packs to the neck, axillae, and groin as adjunctive cooling measures during induction. These high blood flow areas accelerate heat transfer and help you reach target temperature faster. Remove ice packs once your core temperature drops to 36°C to prevent overshooting your target. Consider infusing 500-1000 ml of refrigerated (4°C) normal saline over 20-30 minutes if you need rapid initial cooling, but limit total cold fluid volume to 30 ml/kg to avoid pulmonary oedema and electrolyte dilution.
Check core temperature every 15 minutes during active cooling. Your cooling rate should not exceed 1°C per hour because faster rates increase arrhythmia risk and make precise temperature control difficult. Adjust your cooling device settings if temperature drops too rapidly. Most modern systems with feedback control automatically modulate cooling intensity based on the temperature probe reading, but verify device response by reviewing actual temperature trends rather than relying solely on programmed targets.
Physical cooling methods and equipment setup
Your choice between surface and endovascular cooling depends on availability and patient factors. Water-circulating cooling pads provide effective, non-invasive temperature control suitable for most patients undergoing targeted temperature management. Place pads on the chest, back, and thighs for maximum surface area contact. Endovascular catheters achieve tighter temperature control with less overshoot but require femoral or internal jugular access and carry catheter-related infection risk.
Room temperature affects your cooling efficiency. Lower ambient temperature to 18-20°C if possible and remove excess bedding to enhance convective and evaporative heat loss. Wet towels applied to exposed skin create additional evaporative cooling during the induction phase. These simple environmental modifications supplement your primary cooling device without adding cost or complexity.
Effective cooling combines mechanical devices with environmental adjustments and pharmacological shivering suppression to achieve target temperature within 4 hours of initiation.
Managing shivering effectively
Shivering represents the single greatest obstacle to successful cooling. This involuntary muscle contraction generates heat at rates exceeding 400% of basal metabolism, overwhelming your cooling device capacity whilst increasing oxygen consumption, carbon dioxide production, and intracranial pressure. You must aggressively suppress shivering to achieve and maintain your target temperature.
Assess shivering severity using the Bedside Shivering Assessment Scale (BSAS) hourly:
- 0 = No shivering
- 1 = Mild shivering (localised to neck/thorax)
- 2 = Moderate shivering (chest and upper extremities)
- 3 = Severe shivering (whole body)
Apply this stepwise protocol when shivering occurs:
First-line measures (BSAS 0-1):
- Increase sedation (propofol to 50-70 mcg/kg/min)
- Optimise analgesia (fentanyl bolus 50-100 mcg)
- Apply warming blanket to hands and feet (counterwarming)
Second-line measures (BSAS 2):
- Add buspirone 30 mg via nasogastric tube
- OR magnesium sulphate 4 g IV over 15 minutes
- OR dexmedetomidine infusion 0.2-0.7 mcg/kg/hour
Third-line measures (BSAS 3):
- Consider pethidine 25-50 mg IV (lowers shivering threshold)
- Last resort: neuromuscular blockade (rocuronium or vecuronium)
Document your shivering assessments and interventions at each step. Neuromuscular blockade eliminates shivering completely but masks seizure activity and requires continuous electroencephalogram monitoring if prolonged. Reserve paralysis for refractory cases where other measures fail because it complicates neurological assessment and increases infection risk through immobility.
Step 5. Monitor for complications and adjust
Temperature management creates predictable physiological changes that require vigilant monitoring and prompt correction. Your patient remains at risk for multiple complications throughout the cooling and maintenance phases, with some becoming life-threatening if you fail to recognise and treat them quickly. Systematic assessment every hour catches problems early when interventions remain straightforward, preventing cascade failures that compromise your entire protocol and worsen patient outcomes.
Cardiovascular monitoring and adjustments
Hypothermia directly affects cardiac function through multiple mechanisms you must anticipate. Expect heart rate to decrease by 10 beats per minute for each degree below 37°C as cooling slows sinoatrial node automaticity. Bradycardia becomes significant when heart rate drops below 40 beats per minute, potentially reducing cardiac output despite increased stroke volume. Monitor your patient’s mean arterial pressure continuously because peripheral vasoconstriction during cooling increases afterload whilst decreasing cardiac output, creating competing effects on blood pressure.
Check your electrocardiogram for rhythm changes hourly. QT interval prolongation occurs universally during hypothermia, increasing risk for torsades de pointes if your patient receives QT-prolonging medications. Osborn waves (J waves) appear as distinctive positive deflections at the QRS-ST junction when core temperature falls below 32°C, representing a benign finding that resolves with rewarming. Serious arrhythmias remain rare at temperatures above 30°C, but ventricular ectopy warrants immediate assessment for electrolyte abnormalities or excessive cooling below your target.
Cardiovascular monitoring during targeted temperature management requires distinguishing expected physiological responses from pathological complications that demand intervention.
Adjust vasopressor support based on mean arterial pressure trends rather than heart rate alone. Maintain MAP above 65 mmHg as your minimum threshold, increasing noradrenaline as needed during progressive vasoconstriction. Cold-induced diuresis commonly causes hypovolaemia within the first 6 hours of cooling. Replace urine output exceeding 200 ml/hour with additional crystalloid to prevent volume depletion that compromises perfusion.
Electrolyte disturbances and correction
Hypothermia drives potassium, magnesium, and phosphate into cells through altered membrane pump function, creating serum deficiencies that require aggressive replacement. Check electrolytes every 4 hours during cooling and maintenance because deficiencies develop rapidly and predispose to arrhythmias. Your potassium typically drops 0.5-1.0 mmol/L during cooling despite normal total body stores.
Follow this replacement protocol when monitoring how to do targeted temperature management:
Potassium targets and replacement:
- Maintain serum K+ between 4.0-4.5 mmol/L during cooling
- Replace 20-40 mmol KCl for each 0.5 mmol/L below target
- Increase monitoring to every 2 hours during rewarming
Magnesium correction:
- Target Mg2+ above 1.0 mmol/L (higher if arrhythmias present)
- Give 4-8 mmol MgSO4 for levels <0.8 mmol/L
- Recheck 4 hours after replacement
Phosphate management:
- Maintain PO4 above 0.8 mmol/L
- Replace with 20-40 mmol sodium phosphate if deficient
Anticipate the reversal during rewarming when intracellular electrolytes shift back into serum. Hyperkalaemia develops in 20-30% of patients during rewarming, particularly if you replaced aggressively during maintenance. Stop all potassium supplementation 2 hours before beginning rewarming and monitor levels every 2 hours until temperature reaches 36°C.
Recognising and preventing infections
Hypothermia suppresses immune function through multiple pathways that increase infection risk. White blood cell migration and phagocytosis decrease by 30-50% at temperatures below 35°C, whilst cytokine production drops significantly. Pneumonia and catheter-related infections represent your highest risks, with rates doubling compared to normothermic patients in some studies.
Implement strict infection prevention measures from the start. Change central line dressings every 48 hours and inspect sites daily for erythema or discharge. Elevate head of bed to 30 degrees to reduce aspiration pneumonia risk. Perform regular oral care with chlorhexidine every 6 hours. Send cultures promptly if fever develops after rewarming because therapeutic hypothermia masks signs of infection during cooling phases.
Check chest radiographs daily and examine ventilator parameters for increasing oxygen requirements or secretions suggesting pneumonia. Start empirical antibiotics immediately if clinical suspicion warrants because delayed treatment during immunosuppression leads to rapid deterioration. Your threshold for investigation should remain lower than in normothermic patients.
Step 6. Controlled rewarming and fever control
Rewarming represents the most hazardous phase of targeted temperature management. Rapid temperature increases trigger electrolyte shifts that cause fatal arrhythmias whilst precipitating rebound hyperthermia that worsens neurological outcomes. Your rewarming rate must remain strictly controlled at 0.2-0.5°C per hour, making this phase last 6-10 hours depending on your starting temperature. Document the exact time rewarming begins and your target completion time to coordinate nursing care and medication adjustments across shift changes.
Rewarming protocol and rate control
Begin rewarming after completing your 24-hour maintenance period or when clinical circumstances demand earlier termination. Set your cooling device to increase temperature by 0.25°C per hour as the safest approach that minimises complications. Check core temperature every 30 minutes during active rewarming because device programming may not match actual patient response. Adjust your device settings immediately if temperature rises faster than 0.5°C per hour, which increases potassium release and arrhythmia risk substantially.
Continue all sedation, analgesia, and shivering suppression throughout rewarming. Your patient experiences the same shivering triggers during rewarming as during cooling, potentially causing rapid temperature overshoot if suppression medications cease prematurely. Maintain neuromuscular blockade if you used it during maintenance, tapering only after reaching 36°C to prevent sudden muscle activity that accelerates warming.
Preventing rebound hyperthermia
Most patients develop fever within 12-48 hours after reaching normothermia despite completing your protocol. This rebound hyperthermia negates the neuroprotective benefits you achieved through careful temperature control and correlates with worse neurological outcomes in multiple studies. Keep your cooling device in place and active for at least 24 hours after reaching 36-37°C, programming it to prevent temperatures above 37.5°C.
Fever prevention after rewarming remains as critical to neuroprotection as the initial cooling phase, requiring continued vigilance and active temperature control for the full 72-hour post-arrest period.
Monitor temperature hourly after removing active cooling devices. Treat any elevation above 37.5°C immediately with physical cooling measures (ice packs, cooling blankets) and paracetamol 1 g every 6 hours.
Post-protocol fever management
Your temperature control responsibilities extend beyond the formal 72-hour protocol when understanding how to do targeted temperature management comprehensively. Continue monitoring core or peripheral temperature every 4 hours for the next 48 hours because late fever commonly develops. Investigate fever sources systematically through blood cultures, chest radiographs, and urine analysis because pneumonia and catheter infections represent genuine risks after prolonged cooling and mechanical ventilation that require specific antibiotic treatment rather than simple antipyretics.
Additional tips for Australian practice
Australian healthcare settings present specific considerations when implementing temperature management protocols. Your approach must align with ANZCOR guidelines whilst accounting for local resources, transfer distances, and regional variations in care delivery. Understanding these Australian-specific factors ensures you implement targeted temperature management safely within your institutional capabilities.
ANZCOR compliance and documentation
Follow the current ANZCOR Guideline 11.8 as your primary reference when establishing institutional protocols. Your documentation must reflect ANZCOR recommendations for fever prevention as the minimum standard, targeting temperature at or below 37.5°C for all comatose post-arrest patients. State-based regulatory requirements vary, so verify your local health department expectations regarding protocol approval and audit processes. Many Australian hospitals require ethics committee review for temperature management protocols despite widespread acceptance, particularly if you target hypothermia rather than normothermia.
Regional transfer considerations
Patients arrested in regional areas often require transfer to tertiary centres for ongoing care. Do not initiate cold fluid infusion during retrieval because evidence shows prehospital cooling offers no benefit and may cause harm. Instead, focus on preventing fever during transport using simple measures like uncovering the patient and adjusting ambient temperature in the aircraft or ambulance. Communicate your temperature management plan clearly with the receiving intensive care team before departure to ensure continuity of care and appropriate bed allocation in units equipped with cooling devices and continuous monitoring capabilities.
Regional practitioners should prioritise haemodynamic stabilisation and fever prevention during transfer rather than attempting complex cooling protocols in transport environments.
Bringing it all together
You now have a systematic approach to targeted temperature management that protects your comatose cardiac arrest patients from secondary brain injury. The protocol requires confirming indications, stabilising your patient, preventing fever above 37.5°C, managing shivering aggressively, monitoring for complications hourly, and executing controlled rewarming. Each step builds on the previous one, creating a coordinated care pathway that spans 72 hours minimum.
Success depends on meticulous attention to physiological details rather than simply attaching cooling devices. Your vigilance during electrolyte monitoring, shivering suppression, and fever prevention determines whether patients achieve the neurological outcomes this intervention promises. Practice these skills systematically and your confidence will grow with each case.
Advanced Life Support training provides structured education in post-resuscitation care including temperature management protocols. Explore our ALS courses to develop practical competence in these critical interventions through hands-on simulation and expert instruction.
